Advances in pharmacotherapy for treating female sexual dysfunction

Rossella E. Nappi, Laura Cucinella

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Introduction: 'Female sexual dysfunction' (FSD) is an umbrella term comprising a range of common disorders, including hypoactive sexual desire, reduced subjective and/or physical genital arousal (poor sensation, vasocongestion, lubrication), sexual pain and inability to achieve orgasm/satisfaction, which are multidimensional by nature and often coexisting. Psychological and contextual factors have a significant influence on organic components of sexual response and behavior and a tailored medical approach to sexual symptoms is inevitably limited.Areas covered: The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model. Hormone therapy, including estrogens, testosterone, tibolone and dehydroepiandrosterone, are discussed in term of efficacy and safety in postmenopausal women both for female sexual interest/arousal disorder (FSIAD) and genito-pelvic pain/penetration disorder. Ospemifene, a selective estrogen receptor modulator, approved to treat dyspareunia at menopause, is also discussed. Data on psychoactive agents for treatment of FSIAD in premenopausal women are discussed, including the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.Expert opinion: We are still waiting for an approved pharmacotherapy for FSD. This is not the result of gender inequality in sexual medicine, but it reflects the need of balancing benefits and risks in order to provide effective and safe treatments to women of any age.

Original languageEnglish
Pages (from-to)875-887
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number6
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Psychological Sexual Dysfunctions
Drug Therapy
tibolone
Testosterone
Buspirone
Orgasm
Lubrication
Dyspareunia
Selective Estrogen Receptor Modulators
Somatoform Disorders
Pelvic Pain
Dehydroepiandrosterone
Psychotropic Drugs
Expert Testimony
Therapeutics
Menopause
Arousal
Sexual Behavior
Estrogens
Medicine

Keywords

  • Dehydroepiandrosterone
  • Female sexual interest/arousal disorder
  • Genito-pelvic pain/penetration disorder
  • Hormone therapy
  • Local estrogen therapy
  • Ospemifene
  • Psychoactive drugs
  • Testosterone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Advances in pharmacotherapy for treating female sexual dysfunction. / Nappi, Rossella E.; Cucinella, Laura.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 6, 01.04.2015, p. 875-887.

Research output: Contribution to journalArticle

@article{b5671fa26fbd4b2b955aec3fba9facf0,
title = "Advances in pharmacotherapy for treating female sexual dysfunction",
abstract = "Introduction: 'Female sexual dysfunction' (FSD) is an umbrella term comprising a range of common disorders, including hypoactive sexual desire, reduced subjective and/or physical genital arousal (poor sensation, vasocongestion, lubrication), sexual pain and inability to achieve orgasm/satisfaction, which are multidimensional by nature and often coexisting. Psychological and contextual factors have a significant influence on organic components of sexual response and behavior and a tailored medical approach to sexual symptoms is inevitably limited.Areas covered: The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model. Hormone therapy, including estrogens, testosterone, tibolone and dehydroepiandrosterone, are discussed in term of efficacy and safety in postmenopausal women both for female sexual interest/arousal disorder (FSIAD) and genito-pelvic pain/penetration disorder. Ospemifene, a selective estrogen receptor modulator, approved to treat dyspareunia at menopause, is also discussed. Data on psychoactive agents for treatment of FSIAD in premenopausal women are discussed, including the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.Expert opinion: We are still waiting for an approved pharmacotherapy for FSD. This is not the result of gender inequality in sexual medicine, but it reflects the need of balancing benefits and risks in order to provide effective and safe treatments to women of any age.",
keywords = "Dehydroepiandrosterone, Female sexual interest/arousal disorder, Genito-pelvic pain/penetration disorder, Hormone therapy, Local estrogen therapy, Ospemifene, Psychoactive drugs, Testosterone",
author = "Nappi, {Rossella E.} and Laura Cucinella",
year = "2015",
month = "4",
day = "1",
doi = "10.1517/14656566.2015.1020791",
language = "English",
volume = "16",
pages = "875--887",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Advances in pharmacotherapy for treating female sexual dysfunction

AU - Nappi, Rossella E.

AU - Cucinella, Laura

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Introduction: 'Female sexual dysfunction' (FSD) is an umbrella term comprising a range of common disorders, including hypoactive sexual desire, reduced subjective and/or physical genital arousal (poor sensation, vasocongestion, lubrication), sexual pain and inability to achieve orgasm/satisfaction, which are multidimensional by nature and often coexisting. Psychological and contextual factors have a significant influence on organic components of sexual response and behavior and a tailored medical approach to sexual symptoms is inevitably limited.Areas covered: The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model. Hormone therapy, including estrogens, testosterone, tibolone and dehydroepiandrosterone, are discussed in term of efficacy and safety in postmenopausal women both for female sexual interest/arousal disorder (FSIAD) and genito-pelvic pain/penetration disorder. Ospemifene, a selective estrogen receptor modulator, approved to treat dyspareunia at menopause, is also discussed. Data on psychoactive agents for treatment of FSIAD in premenopausal women are discussed, including the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.Expert opinion: We are still waiting for an approved pharmacotherapy for FSD. This is not the result of gender inequality in sexual medicine, but it reflects the need of balancing benefits and risks in order to provide effective and safe treatments to women of any age.

AB - Introduction: 'Female sexual dysfunction' (FSD) is an umbrella term comprising a range of common disorders, including hypoactive sexual desire, reduced subjective and/or physical genital arousal (poor sensation, vasocongestion, lubrication), sexual pain and inability to achieve orgasm/satisfaction, which are multidimensional by nature and often coexisting. Psychological and contextual factors have a significant influence on organic components of sexual response and behavior and a tailored medical approach to sexual symptoms is inevitably limited.Areas covered: The paper reports the most recent advances in pharmacotherapy for women taking into account the biopsychosocial model. Hormone therapy, including estrogens, testosterone, tibolone and dehydroepiandrosterone, are discussed in term of efficacy and safety in postmenopausal women both for female sexual interest/arousal disorder (FSIAD) and genito-pelvic pain/penetration disorder. Ospemifene, a selective estrogen receptor modulator, approved to treat dyspareunia at menopause, is also discussed. Data on psychoactive agents for treatment of FSIAD in premenopausal women are discussed, including the potential use of on-demand combined hormonal (testosterone) and non-hormonal (buspirone or sildenafil) treatments to address possible neurophysiological profiles of women.Expert opinion: We are still waiting for an approved pharmacotherapy for FSD. This is not the result of gender inequality in sexual medicine, but it reflects the need of balancing benefits and risks in order to provide effective and safe treatments to women of any age.

KW - Dehydroepiandrosterone

KW - Female sexual interest/arousal disorder

KW - Genito-pelvic pain/penetration disorder

KW - Hormone therapy

KW - Local estrogen therapy

KW - Ospemifene

KW - Psychoactive drugs

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=84925862485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925862485&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1020791

DO - 10.1517/14656566.2015.1020791

M3 - Article

C2 - 25732267

AN - SCOPUS:84925862485

VL - 16

SP - 875

EP - 887

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -